|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SGK2 |
Gene summary for SGK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SGK2 | Gene ID | 10110 |
| Gene name | serum/glucocorticoid regulated kinase 2 | |
| Gene Alias | H-SGK2 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q9HBY8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10110 | SGK2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.59e-04 | 4.06e-01 | -0.1808 |
| 10110 | SGK2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 9.70e-03 | 2.81e-01 | -0.0811 |
| 10110 | SGK2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.09e-12 | 4.72e-01 | -0.1954 |
| 10110 | SGK2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.38e-03 | 4.34e-01 | -0.1207 |
| 10110 | SGK2 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.23e-02 | 3.53e-01 | -0.1526 |
| 10110 | SGK2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.55e-06 | 4.17e-01 | -0.059 |
| 10110 | SGK2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.52e-04 | 6.59e-01 | -0.1706 |
| 10110 | SGK2 | A002-C-116 | Human | Colorectum | FAP | 3.07e-03 | -1.01e-01 | -0.0452 |
| 10110 | SGK2 | NAFLD1 | Human | Liver | NAFLD | 1.43e-03 | 5.60e-01 | -0.04 |
| 10110 | SGK2 | HCC1_Meng | Human | Liver | HCC | 1.38e-30 | 1.18e-02 | 0.0246 |
| 10110 | SGK2 | HCC2 | Human | Liver | HCC | 7.26e-04 | 2.81e+00 | 0.5341 |
| 10110 | SGK2 | S029 | Human | Liver | HCC | 3.18e-05 | 3.84e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006979 | Colorectum | AD | response to oxidative stress | 145/3918 | 446/18723 | 5.16e-09 | 3.23e-07 | 145 |
| GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
| GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
| GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
| GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
| GO:0032411 | Colorectum | AD | positive regulation of transporter activity | 37/3918 | 120/18723 | 6.82e-03 | 4.22e-02 | 37 |
| GO:00069791 | Colorectum | SER | response to oxidative stress | 114/2897 | 446/18723 | 1.75e-08 | 1.28e-06 | 114 |
| GO:00015581 | Colorectum | SER | regulation of cell growth | 90/2897 | 414/18723 | 4.00e-04 | 6.02e-03 | 90 |
| GO:00160491 | Colorectum | SER | cell growth | 100/2897 | 482/18723 | 1.07e-03 | 1.24e-02 | 100 |
| GO:00324111 | Colorectum | SER | positive regulation of transporter activity | 31/2897 | 120/18723 | 2.25e-03 | 2.16e-02 | 31 |
| GO:00181051 | Colorectum | SER | peptidyl-serine phosphorylation | 66/2897 | 315/18723 | 5.47e-03 | 4.06e-02 | 66 |
| GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
| GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
| GO:00069794 | Colorectum | FAP | response to oxidative stress | 102/2622 | 446/18723 | 2.29e-07 | 1.33e-05 | 102 |
| GO:00015583 | Colorectum | FAP | regulation of cell growth | 95/2622 | 414/18723 | 5.02e-07 | 2.61e-05 | 95 |
| GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
| GO:00182092 | Colorectum | FAP | peptidyl-serine modification | 73/2622 | 338/18723 | 8.47e-05 | 1.51e-03 | 73 |
| GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
| GO:00324113 | Colorectum | FAP | positive regulation of transporter activity | 29/2622 | 120/18723 | 1.97e-03 | 1.65e-02 | 29 |
| GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa04068 | Liver | NAFLD | FoxO signaling pathway | 30/1043 | 131/8465 | 4.91e-04 | 8.05e-03 | 6.49e-03 | 30 |
| hsa040681 | Liver | NAFLD | FoxO signaling pathway | 30/1043 | 131/8465 | 4.91e-04 | 8.05e-03 | 6.49e-03 | 30 |
| hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
| hsa040685 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SGK2 | SNV | Missense_Mutation | c.187N>C | p.Ser63Pro | p.S63P | Q9HBY8 | protein_coding | deleterious(0.03) | benign(0.097) | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| SGK2 | SNV | Missense_Mutation | c.116N>T | p.Pro39Leu | p.P39L | Q9HBY8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SGK2 | SNV | Missense_Mutation | novel | c.982N>T | p.Leu328Phe | p.L328F | Q9HBY8 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SGK2 | SNV | Missense_Mutation | novel | c.629N>C | p.Leu210Pro | p.L210P | Q9HBY8 | protein_coding | deleterious(0.01) | possibly_damaging(0.867) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SGK2 | SNV | Missense_Mutation | rs778281277 | c.188C>G | p.Ser63Cys | p.S63C | Q9HBY8 | protein_coding | deleterious(0.04) | benign(0.334) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SGK2 | SNV | Missense_Mutation | c.99N>A | p.Met33Ile | p.M33I | Q9HBY8 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD | |
| SGK2 | SNV | Missense_Mutation | rs774838630 | c.943G>A | p.Gly315Arg | p.G315R | Q9HBY8 | protein_coding | tolerated(0.48) | benign(0.051) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| SGK2 | insertion | Nonsense_Mutation | novel | c.631_632insGGCAGGCGGGCAGGTGAAAAAAAAAGAAAAG | p.His211ArgfsTer6 | p.H211Rfs*6 | Q9HBY8 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SGK2 | deletion | Frame_Shift_Del | novel | c.1268delN | p.Asp423AlafsTer34 | p.D423Afs*34 | Q9HBY8 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SGK2 | SNV | Missense_Mutation | novel | c.446A>C | p.Lys149Thr | p.K149T | Q9HBY8 | protein_coding | deleterious(0.01) | possibly_damaging(0.901) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 328083523 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | ILORASERTIB | ILORASERTIB | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | PHA-767491 | CHEMBL225519 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | PF-562271 | PF-00562271 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | RG-1530 | RG-1530 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | CENISERTIB | CENISERTIB | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | SB-220025 | SB-220025 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | CYC-116 | CYC-116 | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | SOTRASTAURIN | SOTRASTAURIN | ||
| 10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | GSK-269962A | GSK-269962A |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |